Search Results - "Byrd, C."

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL by Hallek, Michael, Cheson, Bruce D., Catovsky, Daniel, Caligaris-Cappio, Federico, Dighiero, Guillermo, Döhner, Hartmut, Hillmen, Peter, Keating, Michael, Montserrat, Emili, Chiorazzi, Nicholas, Stilgenbauer, Stephan, Rai, Kanti R., Byrd, John C., Eichhorst, Barbara, O'Brien, Susan, Robak, Tadeusz, Seymour, John F., Kipps, Thomas J.

“…The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad…”
Get full text

The B-cell receptor signaling pathway as a therapeutic target in CLL by Woyach, Jennifer A., Johnson, Amy J., Byrd, John C.

“…Targeted therapy with imatinib and other selective tyrosine kinase inhibitors has transformed the treatment of chronic myeloid leukemia. Unlike chronic myeloid…”
Get full text

Hypertension and incident cardiovascular events following ibrutinib initiation by Dickerson, Tyler, Wiczer, Tracy, Waller, Allyson, Philippon, Jennifer, Porter, Kyle, Haddad, Devin, Guha, Avirup, Rogers, Kerry A., Bhat, Seema, Byrd, John C., Woyach, Jennifer A., Awan, Farrukh, Addison, Daniel

“…Ibrutinib is associated with dramatic efficacy against B-cell malignancies. Yet, it has been linked with potentially limiting cardiotoxicity, including…”
Get full text

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial by Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech

“…Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy…”
Get full text

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation by Buhimschi, Alexandru D, Armstrong, Haley A, Toure, Momar, Jaime-Figueroa, Saul, Chen, Timothy L, Lehman, Amy M, Woyach, Jennifer A, Johnson, Amy J, Byrd, John C, Crews, Craig M

“…Inhibition of Bruton’s tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with…”
Get full text

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience by O'Brien, Susan, Furman, Richard R., Coutre, Steven, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Wierda, William, Jones, Jeffrey, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Luan, Ying, James, Danelle F., Chu, Alvina D., Byrd, John C.

“…We previously reported durable responses and manageable safety of ibrutinib from a 3-year follow-up of treatment-naïve (TN) older patients (≥65 years of age)…”
Get full text

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G., Seymour, John F.

“…To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously…”
Get full text

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia by Byrd, John C, Harrington, Bonnie, O’Brien, Susan, Jones, Jeffrey A, Schuh, Anna, Devereux, Steve, Chaves, Jorge, Wierda, William G, Awan, Farrukh T, Brown, Jennifer R, Hillmen, Peter, Stephens, Deborah M, Ghia, Paolo, Barrientos, Jacqueline C, Pagel, John M, Woyach, Jennifer, Johnson, Dave, Huang, Jane, Wang, Xiaolin, Kaptein, Allard, Lannutti, Brian J, Covey, Todd, Fardis, Maria, McGreivy, Jesse, Hamdy, Ahmed, Rothbaum, Wayne, Izumi, Raquel, Diacovo, Thomas G, Johnson, Amy J, Furman, Richard R

“…Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had…”
Get full text

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab by Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.

“…Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase…”
Get full text

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia by Woyach, Jennifer A, Ruppert, Amy S, Guinn, Daphne, Lehman, Amy, Blachly, James S, Lozanski, Arletta, Heerema, Nyla A, Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L, McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A, Flynn, Joseph M, Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A, Awan, Farrukh T, Blum, Kristie A, Grever, Michael R, Lozanski, Gerard, Johnson, Amy J, Byrd, John C

Get full text

Harmonic Vibrational Frequencies: Approximate Global Scaling Factors for TPSS, M06, and M11 Functional Families Using Several Common Basis Sets by Kashinski, D. O, Chase, G. M, Nelson, R. G, Di Nallo, O. E, Scales, A. N, VanderLey, D. L, Byrd, E. F. C

“…We propose new approximate global multiplicative scaling factors for the DFT calculation of ground state harmonic vibrational frequencies using functionals…”
Get full text

Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model by Halley, Patrick D., Lucas, Christopher R., McWilliams, Emily M., Webber, Matthew J., Patton, Randy A., Kural, Comert, Lucas, David M., Byrd, John C., Castro, Carlos E.

“…Many cancers show primary or acquired drug resistance due to the overexpression of efflux pumps. A novel mechanism to circumvent this is to integrate drugs,…”
Get full text

Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies by Guha, Avirup, Derbala, Mohamed H., Zhao, Qiuhong, Wiczer, Tracy E., Woyach, Jennifer A., Byrd, John C., Awan, Farrukh T., Addison, Daniel

“…VA-associated symptoms included chest pain, palpitations, dizziness, syncope, heart failure (HF) symptoms, and sudden cardiac death. [...]subgroup analysis…”
Get full text

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib by Woyach, Jennifer A, Furman, Richard R, Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S, Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M, Versele, Matthias, Dave, Sandeep S, Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M, Blum, Kristie A, Lozanski, Arletta, Lozanski, Gerard, James, Danelle F, Barrientos, Jacqueline C, Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J, Chang, Betty Y, Johnson, Amy J, Byrd, John C

“…In some patients with CLL, resistance to the BTK inhibitor ibrutinib develops. Two classes of resistance mutations have been found: the more common involves…”
Get full text

Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function by Stiff, Andrew, Trikha, Prashant, Mundy-Bosse, Bethany, McMichael, Elizabeth, Mace, Thomas A, Benner, Brooke, Kendra, Kari, Campbell, Amanda, Gautam, Shalini, Abood, David, Landi, Ian, Hsu, Vincent, Duggan, Megan, Wesolowski, Robert, Old, Matthew, Howard, John Harrison, Yu, Lianbo, Stasik, Nancy, Olencki, Thomas, Muthusamy, Natarajan, Tridandapani, Susheela, Byrd, John C, Caligiuri, Michael, Carson, William E

“…mAbs are used to treat solid and hematologic malignancies and work in part through Fc receptors (FcRs) on natural killer cells (NK). However, FcR-mediated…”
Get full text

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling by Yeh, Yuh-Ying, Ozer, Hatice Gulcin, Lehman, Amy M., Maddocks, Kami, Yu, Lianbo, Johnson, Amy J., Byrd, John C.

“…Multiple studies show that chronic lymphocytic leukemia (CLL) cells are heavily dependent on their microenvironment for survival. Communication between CLL…”
Get full text

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia by Oakes, Christopher C, Seifert, Marc, Assenov, Yassen, Gu, Lei, Przekopowitz, Martina, Ruppert, Amy S, Wang, Qi, Imbusch, Charles D, Serva, Andrius, Koser, Sandra D, Brocks, David, Lipka, Daniel B, Bogatyrova, Olga, Weichenhan, Dieter, Brors, Benedikt, Rassenti, Laura, Kipps, Thomas J, Mertens, Daniel, Zapatka, Marc, Lichter, Peter, Döhner, Hartmut, Küppers, Ralf, Zenz, Thorsten, Stilgenbauer, Stephan, Byrd, John C, Plass, Christoph

“…Christoph Plass, Christopher Oakes and colleagues study genome-wide DNA methylation dynamics during B cell maturation and the pathogenic role of transcription…”
Get full text

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials by Brown, Jennifer R, Moslehi, Javid, O'Brien, Susan, Ghia, Paolo, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D, Fraser, Graeme, Rule, Simon, Kipps, Thomas J, Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C, Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F, Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle, Burger, Jan A

“…The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been…”
Get full text

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 by Herman, Sarah E.M., Gordon, Amber L., Hertlein, Erin, Ramanunni, Asha, Zhang, Xiaoli, Jaglowski, Samantha, Flynn, Joseph, Jones, Jeffrey, Blum, Kristie A., Buggy, Joseph J., Hamdy, Ahmed, Johnson, Amy J., Byrd, John C.

“…B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) is essential to BCR signaling and…”
Get full text

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody by Benson, Don M., Bakan, Courtney E., Mishra, Anjali, Hofmeister, Craig C., Efebera, Yvonne, Becknell, Brian, Baiocchi, Robert A., Zhang, Jianying, Yu, Jianhua, Smith, Megan K., Greenfield, Carli N., Porcu, Pierluigi, Devine, Steven M., Rotem-Yehudar, Rinat, Lozanski, Gerard, Byrd, John C., Caligiuri, Michael A.

“…T-cell expression of programmed death receptor-1 (PD-1) down-regulates the immune response against malignancy by interacting with cognate ligands (eg, PD-L1)…”
Get full text